Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Sets The Pace In Race To $10bn RSV Vaccine Market

80% Efficacy Against Severe Disease In 65+ Group

Executive Summary

Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.

You may also be interested in...



Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study

The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022

GSK Poaches New Vaccines R&D Chief From Pfizer

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel